Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: VLAD who wrote (9707)	6/16/1998 10:39:00 AM
From: VLAD	Read Replies (1) \| Respond to of 23519

Now do you think for one second that CNBC will report the news of this INDEPENDENT study at premiere diabetic clinic? Of course not! They will just wait for another bogus study to come out and then they will make sure that joe public knows all about it. The relationship between Viagra, MUSE and the press has been one of the most sickening examples of the difference between what the realistic picture of the ED situation is and what the press chooses to report. Vivus stock price will recover as it's niche as a safe and effective treatment for ED is filled on a world wide basis. As Edderd points out the Asian cultures will gladly embrace MUSE as an effective and novel treatment. I would conservatively predict that once these markets open we will see at least 4 to 5 times the consumption as in the US. Many US doctors don't want to mess with a treatment that involves some time and proper instruction. Eventually the Viagra failures will come back for more help......hopefully their doctors will be patient enough to give proper instruction on MUSE application.